Nevro Corp. (NYSE: NVRO) has posted a steady session with the stock price holding at USD 5.84. The medical device firm’s market capitalization stands at approximately USD 224 million. This update is relevant for stakeholders tracking healthcare sector stocks and regulatory-compliant trading data.
Company overview
Nevro Corp. is a healthcare company specializing in medical devices designed for the treatment of chronic pain. Incorporated in 2006 and headquartered in Redwood City, California, it develops and commercializes the Senza spinal cord stimulation system. This platform includes the Senza II and Senza Omnia systems, along with its proprietary 10 kHz Therapy for neuromodulation. Products are distributed through a direct sales force, sales agents, and independent distributors, reaching both U.S. and international markets.
The firm operates within the “Medical – Devices” industry, a segment of the broader healthcare sector known for innovation and regulatory oversight. NVRO’s focus remains evidence-based solutions to improve patient quality of life.
Stock performance
As of the latest trading period, Nevro’s shares are priced at USD 5.84. The trading range over the past year has been between USD 3.165 and USD 13.3, reflecting notable volatility typical in emerging healthcare technology companies. The current session has shown no change in price or percentage movement, indicating stability relative to recent fluctuations.
Daily trading volume reached 751,504 shares, below the average volume of 1,299,962 shares. For investors, lower-than-average volume can signal reduced short-term market activity or potential consolidation phases in stock trading. Given the absence of dividend payments, shareholders rely on price appreciation and business growth as primary return mechanisms.
Market position and sector
Within the healthcare sector, Nevro competes in the medical devices space. This market is shaped by innovation, clinical trial outcomes, and reimbursement policies. With a market capitalization of USD 224 million, NVRO occupies a small-to-mid cap position that can appeal to investors seeking growth potential, balanced with sector-specific risks.
World markets increasingly rely on medtech firms for advanced therapies. NVRO’s proprietary technology and international reach position it as a niche player with distinctive offerings.
Governance and leadership
The company is led by CEO Kevin R. Thornal, who oversees strategic direction, product development, and market expansion efforts. Leadership in medical technology demands a strong balance of regulatory compliance and innovation management. Under Thornal’s tenure, NVRO continues to advance its evidence-based neuromodulation platform while navigating competitive pressures.
Full-time employees number 1,099, indicating a substantial operational scale for a firm of its market size. This supports R&D, manufacturing, sales, and regulatory functions critical to sustaining growth.
Key financial data
- Share Price: USD 5.84
- Market Capitalization: USD 224,092,480
- Dividend: None
- 52-Week Range: USD 3.165 – 13.3
- Volume: 751,504
- Average Volume: 1,299,962
These metrics help investors assess valuation, liquidity, and historical price behavior. Lack of dividend yield may indicate reinvestment into growth initiatives rather than income distribution.
Trading details
- Exchange: New York Stock Exchange (NYSE)
- ISIN: US64157F1030
- CUSIP: 64157F103
- CIK: 0001444380
- IPO Date: November 6, 2014
- Currency: USD
These identifiers ensure clarity in regulatory filings, international trading, and cross-market data integration.
FAQ
- Does Nevro pay dividends? No. NVRO currently does not issue dividends.
- How many employees does Nevro have? The company employs 1,099 full-time staff.
- Where is Nevro headquartered? Redwood City, California, USA.
- What is Nevro’s primary industry? Medical device manufacturing for chronic pain treatment.
- When did Nevro go public? November 6, 2014.
Conclusion
Nevro Corp.’s current trading status reflects stability with no price change. The company maintains a specialized market presence in medical devices, backed by proprietary technology, experienced leadership, and a consistent operational scale. Investors should evaluate NVRO within the context of healthcare sector dynamics, innovation cycles, and market volatility.
Disclaimer
This article is for informational purposes only and does not constitute financial advice. Investors should conduct independent research before making investment decisions.
Official source
For full information about the company, see the link below.
https://www.nevro.com